Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2024 | The main challenges that remain in diagnosing AL amyloidosis

Mario Nuvolone, MD, PhD, University of Pavia, Pavia, Italy, outlines key challenges that remain in the diagnosis of light chain (AL) amyloidosis. First, this disease is rare, and often has clinical presentations which mimic other more prevalent conditions. Furthermore, there is limited disease awareness in the medical community, and particularly amongst cardiologists, who, when suspecting amyloidosis, often first think of transthyretin (ATTR) amyloidosis. Finally, even when clinicians suspect AL amyloidosis correctly, the requirement for histological demonstration of amyloid deposits followed by the need for highly advanced diagnostic tools makes the diagnosis itself challenging. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.